The clinical performance is complex and often involves multiple systems. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of this disease requires a comprehensive assessment platform including clinical performance, imaging, laboratory testing and pathological activation.
It can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnosis and treatment plans. Treatment and management of the HLPET evaluation require individual development of treatment plans, typically including drug therapy, rehabilitation interventions, and regular follow-up multi-dimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of HL PET evaluation. The platform serves a team of domestically and internationally authoritative experts in the field of blood tumours in China, providing the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.